Moleculin Biotech Inc. (MBRX)
NASDAQ · Healthcare
Moleculin Biotech Inc. Long Term Debt 2020–2025
Moleculin Biotech Inc. annual long term debt history from 2020 to 2025. Long term debt refers to financial obligations that are due more than one year in the future.
- Moleculin Biotech Inc. long term debt as of December 31, 2025: 222,000, a 37.99% decrease year-over-year.
- Moleculin Biotech Inc. long term debt for 2025 were 222,000, a 37.99% decrease from 2024.
- Moleculin Biotech Inc. long term debt for 2024 were 358,000, a 24.47% decrease from 2023.
- Moleculin Biotech Inc. long term debt for 2023 were 474,000, a 41.49% increase from 2022.
- Moleculin Biotech Inc. long term debt for 2022 were 335,000.
Long Term Debt
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Moleculin Biotech Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2025 | $0 |
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $0 |
| 2020 | $0 |
Moleculin Biotech Inc. Long Term Debt — FAQ
Moleculin Biotech Inc. (MBRX) long term debt over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see MBRX's long term debt history?
The chart and table above show Moleculin Biotech Inc.'s long term debt by year and by quarter, including the growth rate.